FDA Orange Book · active-ingredient family
Acetylcysteine lysine
Acetylcysteine lysine is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:LEGUBETI · NDA 215040
1
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
2
Exclusivity periods
Brand (NDA) products · for solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| LEGUBETIRLD×2 | GALEPHAR | NDA 215040 | — | Feb 13, 2024 |
Marketing exclusivity (2)
- NPNew product exclusivity (3 years)
Feb 13, 2027
in 8 mo
- NPNew product exclusivity (3 years)
Feb 13, 2027
in 8 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Acetylcysteine lysine — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

